Single-dose intraperitoneal radioimmunotherapy with the murine monoclonal antibody I-131 MOv18: Clinical results in patients with minimal residual disease of ovarian cancer
- 31 December 1995
- journal article
- Published by Elsevier in European Journal Of Cancer
- Vol. 31 (5), 686-690
- https://doi.org/10.1016/0959-8049(94)00454-d
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Adjuvant therapy of ovarian cancer with radioactive monoclonal antibodyBritish Journal of Cancer, 1993
- Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis. The Ovarian Cancer Meta-Analysis Project.Journal of Clinical Oncology, 1991
- Radioimmunoscintigraphy of ovarian cancer with the MOv18 monoclonal antibodyEuropean Journal of Cancer and Clinical Oncology, 1991
- Comparative Immunohistochemical Study of Four Monoclonal Antibodies Directed Against Ovarian Carcinoma-Associated AntigensInternational Journal of Gynecological Pathology, 1991
- Intraperitoneal yttrium-90-labeled monoclonal antibody in ovarian cancer.Journal of Clinical Oncology, 1990
- Antibody-guided irradiation of advanced ovarian cancer with intraperitoneally administered radiolabeled monoclonal antibodies.Journal of Clinical Oncology, 1987
- Characterization of human ovarian carcinoma‐associated antigens defined by novel monoclonal antibodies with tumor‐restricted specificityInternational Journal of Cancer, 1987
- Requirements for a treatment planning system for radioimmunotherapyInternational Journal of Radiation Oncology*Biology*Physics, 1985
- RANDOMISED TRIAL COMPARING TWO COMBINATION CHEMOTHERAPY REGIMENS (HEXA-CAF VS CHAP-5) IN ADVANCED OVARIAN CARCINOMAThe Lancet, 1984
- Long-term survival after chemotherapy for advanced epithelial ovarian carcinomaAmerican Journal of Obstetrics and Gynecology, 1984